

## Special Issue

# Molecular Insights into HIV-1 Infection

### Message from the Guest Editor

The FDA's approval of Lenacapavir, a long-acting HIV-1 prevention drug has marked the year 2025 as a significant milestone in anti-retroviral therapy. Recent advancements and breakthroughs in HIV-1 molecular biology have intensified the race to achieve the development of a complete cure for AIDS. A better understanding of the complex interplay between virus and host cell factors at the molecular level will contribute to developing more effective therapeutic strategies. This Special Issue, "Molecular Insights into HIV-1 Infection", seeks manuscripts that investigate the crucial steps of the HIV-1 lifecycle; virus entry into host cell, nuclear trafficking, integration, latency, assembly, egress, and maturation. We additionally encourage the submission of papers that explore the latest technology in this field used to develop novel drug molecules or anti-HIV-1 strategies. Review articles on recent developments in our understanding of HIV-1 biology are also welcome. We look forward to receiving your submissions, hoping to contribute to the development of innovative strategies against HIV-1.

### Guest Editor

Dr. Satya Prakash Singh

Department of Biological Science, Florida State University, Tallahassee, FL, USA

### Deadline for manuscript submissions

31 December 2026



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/250496](https://mdpi.com/si/250496)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).